Immuno-Oncology
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on immuno-oncology including immune checkpoint inhibitors and activators, and modulators of the tumor-microenvironment. The range of products covers industry data as well as in-depth strategic assessment and analysis of immuno-oncology companies, technologies, targets, R&D pipeline as well as market and sales information.
Subscribe to
our newsletters!
Showing all 14 results
- Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 1800.00
- This product provides basic pipeline information on investigational immunotherapeutics targeting CD47 or SIRP-alpha.€ 400.00
- This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
- This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.€ 300.00
- This product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
- This product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
- This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs€ 2500.00
- This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00